1. Home
  2. AVLN vs AEVA Comparison

AVLN vs AEVA Comparison

Compare AVLN & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$27.52

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

N/A

Current Price

$14.28

Market Cap

1.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
AVLN
AEVA
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
AVLN
AEVA
Price
$27.52
$14.28
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
★ $62.25
$30.00
AVG Volume (30 Days)
192.8K
★ 1.2M
Earning Date
08-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.53
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$78.97
Revenue Next Year
N/A
$124.76
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.90
$8.83
52 Week High
$40.17
$31.30

Technical Indicators

Market Signals
Indicator
AVLN
AEVA
Relative Strength Index (RSI) 35.91 38.47
Support Level $25.86 $13.95
Resistance Level $30.45 $14.30
Average True Range (ATR) 2.25 0.81
MACD -0.56 0.05
Stochastic Oscillator 14.12 11.26

Price Performance

Historical Comparison
AVLN
AEVA

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

Share on Social Networks: